MedTrace Logo

Study of S-1 Plus LV for Untreated Metastatic Colorectal Cancer

NCT00891332 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 73

Last updated 2012-01-18

No results posted yet for this study

Summary

This is a multicenter study designed to evaluate the response rate of S-1 plus Leucovorin (1 week on and 1 week off) as first -line treatment for patients with metastatic colorectal cancer.

Conditions

Interventions

DRUG

S-1 plus LV (The combination therapy of S-1 and Leucovorin)

S-1 40-60 mg bid day 1～day 7 LV 25 mg bid day 1～day 7

Sponsors & Collaborators

  • Taiho Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Hideo Baba, M.D. · Graduate School of Medical Sciences Kumamoto University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2011-07-31
Completion
2011-11-30

Countries

  • China
  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00891332 on ClinicalTrials.gov